Children's Hospital Los Angeles and the Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.
J Child Psychol Psychiatry. 2020 Dec;61(12):1279-1281. doi: 10.1111/jcpp.13357.
Precision medicine and biomarker development have become the prevailing paradigm for mental health research. Despite its conceptual elegance and dominance as a research framework, precision medicine has a very limited track record of demonstrable success thus far for mental illnesses, due in varying degrees to the complexity of both the brain and the pathophysiology of mental illnesses, which limits our ability to develop, replicate, and validate biomarkers for use in enhancing clinical care for mental illnesses, especially in high-risk and complex clinical populations. Research and funding priorities should integrate biomarker development and precision medicine interventions that target the robust behavioral, environmental, and social determinants that we know are important for population-based mental health.
精准医学和生物标志物的发展已经成为精神健康研究的主流范式。尽管精准医学在概念上具有优雅性，并作为一种研究框架占据主导地位，但迄今为止，它在精神疾病方面的成功案例非常有限，这在不同程度上是由于大脑的复杂性和精神疾病的病理生理学的复杂性，这限制了我们开发、复制和验证生物标志物的能力，而这些标志物对于增强精神疾病的临床护理是非常重要的，尤其是在高风险和复杂的临床人群中。研究和资金的优先事项应整合生物标志物的发展和精准医学干预措施，以针对我们已知的对基于人群的精神健康很重要的强大的行为、环境和社会决定因素。
